Double Diabetes: A Growing Problem Requiring Solutions

Abstract

The growing proportion of type 1 diabetes mellitus (T1DM) patients with clinical features of insulin resistance (IR) has led to the description of a distinctive T1DM subgroup, still unrecognised by current guidelines, called double diabetes, assumingly associated with poorer metabolic phenotype and increased risk of micro- and macrovascular complications. The main goal of identifying double diabetes, estimated to be present in up to half of T1DM patients, is timely implementation of appropriate therapeutic interventions to reduce the increased risk of chronic complications and other adverse metabolic traits associated with this condition. Proposed diagnostic criteria are largely divided into three different groups: family history of type 2 diabetes mellitus (T2DM), obesity/metabolic syndrome, and IR. Estimated glucose disposal rate may prove the most reliable marker of double diabetes. In addition to general measures (diet, physical activity, antihypertensive, and lipid-lowering medications, etc.) and development of new insulin preparations with more hepatic action, double diabetes patients may derive more benefit from agents developed for T2DM. Indeed, such potentially promising agents include glucagon-like peptide-1 receptor agonists, sodium-glucose contrasporter-2 inhibitors, and their combination. We are now awaiting long-term trials assessing metabolic and vascular benefits of these medications in double diabetes.

Key words

adjunctive therapy - cardiovascular risk - double diabetes - insulin resistance - metabolic syndrome - type 1 diabetes mellitus.

Publication History

Received: 06 January 2021
Received: 02 February 2021

Accepted: 15 February 2021

Article published online:
26 February 2021

• References

• 1 Teupe B, Bergis K. Epidemiological evidence for “double diabetes”. Lancet 1991; 337: 361-362
• 2 Cleland SJ, Fisher BM, Colhoun HM. et al. Insulin resistance in type 1 diabetes: What is ‘double diabetes’ and what are the risks?. Diabetologia 2013; 56: 1462-1470
• 3 Purnell JQ, Hokanson JE, Marcovina SM. et al. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280: 140-146
• 4 Yazici D, Ozben B, Yavuz D. et al. Epicardial adipose tissue thickness in type 1 diabetic patients. Endocrine 2011; 40: 250-255
• 5 Kietsiriroje N, Pearson S, Campbell M. et al. Double diabetes: A distinct high-risk group?. Diabetes Obes Metab 2019; 21: 2609-2618
• 6 Kupriyanova Y, Zaharia OP, Bobrov P. et al. Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus. J Hepatol 2020; S0168-8278: 33817-4
• 7 Cleland SJ. Cardiovascular risk in double diabetes mellitus-when two worlds collide. Nat Rev Endocrinol 2012; 8: 476-485
• 8 Pozzilli P, Buzzetti R. A new expression of diabetes: double diabetes. Trends Endocrinol Metab 2007; 18: 52-57
• 9 Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: The Framingham Offspring Study. Diabetes 2000; 49: 2201-2207
• 10 Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. Pediatr Diabetes 2018; 19: 346-353
• 11 Kibirige M, Metcalf B, Renuka R. et al. Testing the accelerator hypothesis: The relationship between body mass and age at diagnosis of type 1 diabetes. Diabetes Care 2003; 26: 2865-2870
• 12 Gale EAM. To boldly go--or to go too boldly? The accelerator hypothesis revisited. Diabetologia 2007; 50: 1571-1575
• 13 Thorn LM, Forsblom C, Waden J. et al. Effect of parental type 2 diabetes on offspring with type 1 diabetes. Diabetes Care 2009; 32: 63-68
• 14 Roglic G, Colhoun HM, Stevens LK. et al. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: The EURODIAB IDDM Complications Study. Diabet Med 1998; 15: 418-426
• 15 Erbey JR, Kuller LH, Becker DJ. et al. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care 1998; 21: 610-614
• 16 Purnell JQ, Zinman B, Brunzell JD. et al. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation 2013; 127: 180-187
• 17 Purnell JQ, Braffett BH, Zinman B. et al. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care 2017; 40: 1756-1762
• 18 Williams KV, Erbey JR, Becker D. et al. Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes. The Epidemiology of Diabetes Complications Study. Diabetes Care 1999; 22: 1084-1091
• 19 Conway B, Miller RG, Costacou T. et al. Adiposity and mortality in type 1 diabetes. Int J Obes (Lond) 2009; 33: 796-805
• 20 Gingras V, Leroux C, Fortin A. et al. Predictors of cardiovascular risk among patients with type 1 diabetes: a critical analysis of the metabolic syndrome and its components. Diabetes Metab 2017; 43: 217-222
• 21 Thorn LM, Forsblom C, Waden J. et al. Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2009; 32: 950-952
• 22 Davis TM, Bruce DG, Davis WA. Prevalence and prognostic implications of the metabolic syndrome in community-based patients with type 1 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract 2007; 78: 412-417
• 23 DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223
• 24 Donga E, Dekkers OM, Corssmit EP. et al. Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: Systematic review and meta-analysis. Eur J Endocrinol 2015; 173: 101-109
• 25 Schauer IE, Snell-Bergeon JK, Bergman BC. et al. Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes: the CACTI Study. Diabetes 2011; 60: 306-314
• 26 Williams KV, Erbey JR, Becker D. et al. Can clinical factors estimate insulin resistance in type 1 diabetes?. Diabetes 2000; 49: 626-632
• 27 Epstein EJ, Osman JL, Cohen HW. et al. Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. Diabetes Care 2013; 36: 2280-2285
• 28 Nystrom T, Holzmann MJ, Eliasson B. et al. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab 2018; 20: 556-563
• 29 Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care 2007; 30: 707-712
• 30 Orchard TJ, Chang YF, Ferrell RE. et al. Nephropathy in type 1 diabetes: A manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002; 62: 963-970
• 31 Olson JC, Erbey JR, Forrest KY. et al. Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. Metabolism 2002; 51: 248-254
• 32 Orchard TJ, Olson JC, Erbey JR. et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003; 26: 1374-1379
• 33 Pambianco G, Costacou T, Orchard TJ. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: The Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 2007; 30: 1248-1254
• 34 Mudaliar S, Henry RR, Ciaraldi TP. et al. Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes. Diabetes Obes Metab 2016; 18: 17-24
• 35 Johansen RF, Sondergaard E, Linnebjerg H. et al. Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes. Diabetes Obes Metab 2018; 20: 419-426
• 36 Basu A, Pieber TR, Hansen AK. et al. Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. Diabetes Obes Metab 2018; 20: 1615-1622
• 37 Pullman J, Darsow T, Frias JP. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag 2006; 2: 203-212
• 38 Whitehouse F, Kruger DF, Fineman M. et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25: 724-730
• 39 Ratner RE, Dickey R, Fineman M. et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial. Diabet Med 2004; 21: 1204-1212
• 40 Edelman S, Garg S, Frias J. et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006; 29: 2189-2195
• 41 Prospective UK. Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
• 42 Vella S, Buetow L, Royle P. et al. The use of metformin in type 1 diabetes: A systematic review of efficacy. Diabetologia 2010; 53: 809-820
• 43 Libman IM, Miller KM, DiMeglio LA. et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: A randomized clinical trial. JAMA 2015; 314: 2241-2250
• 44 Petrie JR, Chaturvedi N, Ford I. et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): A double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 597-609
• 45 Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18: S10-S15
• 46 Zdravkovic V, Hamilton JK, Daneman D. et al. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J Pediatr 2006; 149: 845-849
• 47 Bhat R, Bhansali A, Bhadada S. et al. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract 2007; 78: 349-354
• 48 Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diabetes Care 2005; 28: 1562-1567
• 49 Yee HS, Fong NT. A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy 1996; 16: 792-805
• 50 Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type I diabetes. Diabetes Care 1997; 20: 248-253
• 51 Riccardi G, Giacco R, Parillo M. et al. Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: A placebo-controlled, double-blind, multicentre study. Diabet Med 1999; 16: 228-232
• 52 Ziaee A, Esmailzahehha N, Honardoost M. Comparison of adjunctive therapy with metformin and acarbose in patients with type-1 diabetes mellitus. Pak J Med Sci 2017; 33: 686-690
• 53 D’Alessio D. Is GLP-1 a hormone: Whether and when?. J Diabetes Investig 2016; 7: 50-55
• 54 Marso SP, Daniels GH, Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322
• 55 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: 1834-1844
• 56 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 2019; 394: 121-130
• 57 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019; 394: 131-138
• 58 Frandsen CS, Dejgaard TF, Holst JJ. et al. Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: A randomized, placebo-controlled, double-blind parallel study. Diabetes Care 2015; 38: 2250-2257
• 59 Dejgaard TF, Frandsen CS, Hansen TS. et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2016; 4: 221-232
• 60 Kuhadiya ND, Dhindsa S, Ghanim H. et al. Addition of liraglutide to insulin in patients with type 1 diabetes: A randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care 2016; 39: 1027-1035
• 61 Mathieu C, Zinman B, Hemmingsson JU. et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: The ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 2016; 39: 1702-1710
• 62 Ahren B, Hirsch IB, Pieber TR. et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: The ADJUNCT TWO randomized trial. Diabetes Care 2016; 39: 1693-1701
• 63 Cahn A, Cernea S, Raz I. An update on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs 2016; 21: 409-419
• 64 Garg S, Moser E, Bode B. et al. Effect of sitagliptin on postprandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 2013; 19: 19-28
• 65 Guo H, Fang C, Huang Y. et al. The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2016; 121: 184-191
• 66 Tentolouris A, Vlachakis P, Tzeravini E. et al. SGLT2 inhibitors: A review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health 2019; 16: 2965
• 67 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128
• 68 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
• 69 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-357
• 70 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295-2306
• 71 McMurray JJ, DeMets DL, Inzucchi SE. et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPAHF). Eur J Heart Fail 2019; 21: 665-675
• 72 Dandona P, Mathieu C, Phillip M. et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care 2018; 41: 2552-2559
• 73 Mathieu C, Rudofsky G, Phillip M. et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial. Diabetes Obes Metab 2020; 22: 1516-1526
• 74 Rosenstock J, Marquard J, Laffel LM. et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 2018; 41: 2560-2569
• 75 Garg SK, Henry RR, Banks P. et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017; 377: 2337-2348
• 76 Soedamah-Muthu SS, Fuller JH, Mulnier HE. et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: A cohort study using the general practice research database. Diabetes Care 2006; 29: 798-804
• 77 Skrha J, Kalousova M, Svarcova J. et al. Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2012; 120: 277-281
• 78 Kuhadiya ND, Ghanim H, Mehta A. et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metabol 2016; 101: 3506-3515
• 79 Haak T, Golz S, Fritsche A. et al. Therapy of type 1 diabetes. Exp Clin Endocrinol Diabetes 2019; 127: S27-S38